Hamlet BioPharma Participates in Swiss Nordic Bio 2024
Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, is proud to announce its participation in the Swiss Nordic Bio 2024 conference, set to take place in Zurich on March 7, 2024. This high-level partnering and investor conference is dedicated to connecting healthcare innovations, investors, and industry leaders from Switzerland and the Nordic countries.
The Swiss Nordic Bio conference gathers Europe's leading executives from the biotech and pharmaceutical sectors, alongside prominent investors. With over 200 participants, including more than 60 investors, the event serves as a platform for collaboration and investment opportunities. Hamlet BioPharma looks forward to engaging in meaningful discussions and establishing new partnerships.
For more information about Swiss Nordic Bio 2024, please visit Swiss Nordic Bio's official website.
For further information, please contact:
Catharina Svanborg, Chairman and Founder of Hamlet BioPharma, +46-709 42 65 49
Martin Erixon, CEO Hamlet BioPharma, +46-733 00 43 77
